NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
暂无分享,去创建一个
D. Matei | A. Berchuck | M. Dwyer | P. Thaker | D. Miller | J. Schorge | K. Behbakht | H. Gray | A. Hakam | G. Konecny | T. Werner | D. Gershenson | E. Eisenhauer | J. Bakkum-Gamez | R. Vargas | Lainie P. Martin | D. Armstrong | Joyce F. Liu | M. Cristea | F. Backes | G. Leiserowitz | K. McLean | Angela Jain | S. Remmenga | L. Barroilhet | A. W. Hendrickson | Sanja Percac-Lima | R. Grisham | A. Karam | M. McHale | D. Stewart | Lisa Hang | Emese Zsíros | Lee-may Chen | M. DeRosa | Ronald D. Alvarez | C. Leath Iii | Viola C Chitiyo | S. Percac-Lima | Lainie P Martin | A. Jain | Lisa E Hang | D. Miller | Charles A Leath Iii
[1] A. Sood,et al. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. , 2022, Gynecologic oncology.
[2] R. L. Hollis,et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial , 2022, The Lancet.
[3] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[4] Kylie L. Gorringe,et al. Genomic analysis of low‐grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities , 2020, The Journal of pathology.
[5] B. Monk,et al. MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Gray,et al. Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Sood,et al. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. , 2019, Gynecologic oncology.
[8] M. Mouret-Reynier,et al. EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study. , 2019, Journal of Clinical Oncology.
[9] A. Berchuck,et al. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage , 2019, Journal of the National Cancer Institute.
[10] J. Prat,et al. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. , 2018, Human pathology.
[11] A. Oza,et al. Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study , 2018, International Journal of Gynecologic Cancer.
[12] H. Weir,et al. Disparities in ovarian cancer survival in the United States (2001‐2009): Findings from the CONCORD‐2 study , 2017, Cancer.
[13] J. Ruterbusch,et al. Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race/Ethnicity and Histologic Subtypes , 2017, Cancer Epidemiology, Biomarkers & Prevention.
[14] A. Secord,et al. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. , 2017, Gynecologic oncology.
[15] D. Bodurka,et al. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] I. Shih,et al. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? , 2016, Gynecologic oncology.
[17] F. Chauvin,et al. Prognostic factors for overall survival in elderly patients with advanced ovarian cancer treated with chemotherapy: Results of a pooled analysis of three GINECO phase II trials. , 2016, Gynecologic oncology.
[18] Jason D. Wright,et al. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Joshy George,et al. Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.
[20] Jae-Weon Kim,et al. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas , 2014, International Journal of Gynecologic Cancer.
[21] D. Katsaros,et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. , 2014, The Lancet. Oncology.
[22] B. Weber,et al. Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] J. Prat. New insights into ovarian cancer pathology. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] D. Bodurka,et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. , 2012, Gynecologic oncology.
[25] K. Kinzler,et al. Low‐grade serous carcinomas of the ovary contain very few point mutations , 2012, The Journal of pathology.
[26] J. Thigpen. Reclassification of Serous Ovarian Carcinoma by a 2-Tier System: A Gynecologic Oncology Group Study , 2012 .
[27] Kathleen M. Fairfield,et al. Completion of adjuvant chemotherapy and use of health services for older women with epithelial ovarian cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Supriya G Mohile,et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] D. Armstrong,et al. Recent progress in the diagnosis and treatment of ovarian cancer , 2011, CA: a cancer journal for clinicians.
[30] S. Mok,et al. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. , 2010, The American journal of pathology.
[31] A. Sood,et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. , 2009, Gynecologic oncology.
[32] S. Pignata,et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. , 2008, Critical reviews in oncology/hematology.
[33] S. Loibl,et al. Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] B. Weber,et al. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] A. Whittemore,et al. Patterns and Progress in Ovarian Cancer Over 14 Years , 2006, Obstetrics and gynecology.
[36] A. Sood,et al. Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary , 2006, Obstetrics and gynecology.
[37] B. Weber,et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] Michael T Deavers,et al. Grading Ovarian Serous Carcinoma Using a Two-Tier System , 2004, The American journal of surgical pathology.
[39] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.